Pacira BioSciences Reports Q2 2026 Financial Results
Pacira BioSciences reported Q2 2026 revenue growth of 6% and closed a $140M divestiture of iovera to Zimmer Biomet, positioning the company for future innovation.
View filing at SEC.gov →2 most recent filings and news items mentioning PCRX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/PCRX/news?limit=20"
Pull PCRX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayPacira BioSciences reported Q2 2026 revenue growth of 6% and closed a $140M divestiture of iovera to Zimmer Biomet, positioning the company for future innovation.
View filing at SEC.gov →Pacira BioSciences is divesting its iovera business to bolster its balance sheet and focus on biopharmaceuticals. The strategic M&A deal provides immediate cash flow to pay down debt while streamlining operations for growth.
View filing at SEC.gov →